Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response

Several studies suggested that efficacy of tenofovir in reducing the risk of the development of hepatocellular carcinoma (HCC) might be better than that of entecavir. It remains unknown whether a change in therapy can further reduce the risk of HCC in patients receiving entecavir therapy and achieved goal of antiviral therapy, a maintained undetectable hepatitis B virus (HBV) DNA level in the serum.

[1]  Y. Lim,et al.  Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Siddharth Singh,et al.  Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta‐Analysis , 2020, Hepatology.

[3]  B. Carr,et al.  Inflammatory Mechanisms of HCC Development , 2020, Cancers.

[4]  Wukui Cao,et al.  Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  H. Vahaboğlu,et al.  Tenofovir for the Prevention of HCC in Patients With Cirrhosis. , 2019, The American journal of gastroenterology.

[6]  M. Yuen,et al.  A large real‐world cohort study examining the effects of long‐term entecavir on hepatocellular carcinoma and HBsAg seroclearance , 2019, Journal of viral hepatitis.

[7]  J. Sutinen,et al.  Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. , 2019, AIDS patient care and STDs.

[8]  J. Jang,et al.  Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis , 2019, Gut.

[9]  Rui Huang,et al.  Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. , 2019, The American journal of gastroenterology.

[10]  Y. Tse,et al.  Tenofovir is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. , 2019, Gastroenterology.

[11]  M. N. Kim,et al.  A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea. , 2019, Journal of hepatology.

[12]  KASL clinical practice guidelines for management of chronic hepatitis B , 2019, Clinical and molecular hepatology.

[13]  S. Ahn,et al.  Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals , 2019, Scientific Reports.

[14]  Hyo Jeong Kim,et al.  Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study , 2019, JAMA oncology.

[15]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[16]  S. Kottilil,et al.  Chronic Hepatitis B Infection: A Review , 2018, JAMA.

[17]  Y. Kim,et al.  Current status and strategies for hepatitis B control in Korea , 2017, Clinical and molecular hepatology.

[18]  D. Sinn,et al.  Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment , 2017, Hepatology.

[19]  J. Park,et al.  Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients , 2017, BMC Gastroenterology.

[20]  J. R. Rebello Pinho,et al.  High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. , 2017, Annals of hepatology.

[21]  T. Tseng,et al.  Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[22]  D. Sinn,et al.  Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response , 2016, The Korean journal of internal medicine.

[23]  M. Buti,et al.  Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study , 2016, Journal of clinical gastroenterology.

[24]  T. Therneau,et al.  Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B , 2015, Cancer.

[25]  Korea,et al.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma , 2015, Gut and liver.

[26]  R. Idilman,et al.  Long‐term entecavir or tenofovir disoproxil fumarate therapy in treatment‐naïve chronic hepatitis B patients in the real‐world setting , 2015, Journal of viral hepatitis.

[27]  R. Paredes,et al.  The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Jaw-Town Lin,et al.  Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. , 2014, Gastroenterology.

[29]  V. Wong,et al.  Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis , 2013, Hepatology.

[30]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[31]  Chang Duck Kim,et al.  Prognosis of hepatitis B‐related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents , 2012, Journal of gastroenterology and hepatology.

[32]  H. Yim,et al.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B , 2012, Clinical and molecular hepatology.

[33]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[34]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[35]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[36]  C. W. Kim,et al.  Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea , 2005, Journal of Korean medical science.

[37]  G. Práctica,et al.  European Association for the Study of the Liver , 1971 .

[38]  S. Alavian,et al.  Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. , 2017, Annals of hepatology.

[39]  T. Therneau,et al.  Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  [Practice guidelines for management of hepatocellular carcinoma 2009]. , 2009, The Korean journal of hepatology.

[41]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[42]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.